drugset / Trial / NCT07697833
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
Phase 4
Not yet recruiting
500 enrolled
National Institute of Cardiovascular Diseases, Pakistan
Horizon Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction
Timeline
- Start
- 2026-07-15
- Primary completion
- 2027-05-15
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vericiguat | Other / unclassified | 10 mg | Oral |